The tweet was deleted by the author.
But we saved everything 🙂.
Karyopharm Therapeutics revealed new data from its Phase 3 SENTRY trial in myelofibrosis during a late-breaking oral presentation at ASCO26.
The company announced that the results are being published simultaneously in the Journal of Clinical Oncology by ASCO, with further details available for review in the released manuscript. This update marks a significant progression in ongoing myelofibrosis research.
Karyopharm previously reported first-quarter results and outlined key near term milestones for its cancer and myelofibrosis programs in an earlier update. The company cited progress in both its endometrial cancer and myelofibrosis pipelines in that Q1 announcement. These developments provide context for the latest Phase 3 trial data.